z-logo
open-access-imgOpen Access
Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
Author(s) -
Keun Bon Ku,
Hye Jin Shin,
Hae Soo Kim,
BumTae Kim,
SeongJun Kim,
Chonsaeng Kim
Publication year - 2020
Publication title -
journal of microbiology and biotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 64
eISSN - 1738-8872
pISSN - 1017-7825
DOI - 10.4014/jmb.2009.09009
Subject(s) - repurposing , covid-19 , virology , drug repositioning , medicine , coronavirus , pandemic , pharmacology , approved drug , drug , outbreak , biology , infectious disease (medical specialty) , disease , ecology , pathology
COVID-19, caused by the novel coronavirus SARS-CoV-2, has spread globally and caused serious social and economic problems. The WHO has declared this outbreak a pandemic. Currently, there are no approved vaccines or antiviral drugs that prevent SARS-CoV-2 infection. Drugs already approved for clinical use would be ideal candidates for rapid development as COVID-19 treatments. In this work, we screened 1,473 FDA-approved drugs to identify inhibitors of SARS-CoV-2 infection using cell-based assays. The antiviral activity of each compound was measured based on the immunofluorescent staining of infected cells using anti-dsRNA antibody. Twenty-nine drugs among those tested showed antiviral activity against SARS-CoV-2. We report this new list of inhibitors to quickly provide basic information for consideration in developing potential therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom